-
2 weeks ago | 
psychiatrictimes.com | Leah Kuntz
Roche presented interim trial data for trontinemab, a novel anti-amyloid monoclonal antibody, to clinically validate its proprietary Brainshuttle technology for the treatment of prodromal or mild to moderate Alzheimer disease (AD), at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.
-
3 weeks ago | 
psychiatrictimes.com | Leah Kuntz
During the 40th anniversary of Psychiatric Times, we are taking a look back at our covers over the last 5 years. 2020At 9:02AM on the morning of April 19, 1995, a rental truck filled with explosives was detonated outside the Alfred P. Murrah Federal Building in Oklahoma City. Phebe Tucker, MD, DLFAPA, reflected on the events of this tragedy 25 years later in our April 2020 cover.
-
3 weeks ago | 
psychiatrictimes.com | Leah Kuntz
Vanda Pharmaceuticals has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) requesting marketing approval of milsaperidone (Bysanti, also known as VHX-896 and P-88) for the treatment of patients with acute bipolar I disorder and schizophrenia. The NDA is supported by several clinical studies assessing the efficacy and safety of Bysanti.
-
3 weeks ago | 
psychiatrictimes.com | Leah Kuntz
Sleep disorders profoundly influence psychiatric symptoms, necessitating targeted interventions to improve patient outcomes. Clinicians are encouraged to share best practices, case studies, and articles to enhance understanding of sleep-related disorders. Contributions will be featured in an April content series, with potential inclusion in future reports or print issues. SHOW MOREDo you want to be featured in a future Special Report?
-
3 weeks ago | 
psychiatrictimes.com | Leah Kuntz
The first quarter of 2025 saw some huge successes and fails in the psychiatric treatment pipeline. Here, learn more about what percentage of that news was positive vs negative, what disease states were most prominently featured, and what treatments you should keep an eye on. Check out all the specifics of our coverage from the from the first quarter below.
-
3 weeks ago | 
psychiatrictimes.com | Leah Kuntz
LB Pharmaceuticals presented additional positive data from NOVA1, a phase 2 clinical trial of N-methyl amisulpride (LB-102) in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society (SIRS) being held in Chicago, Illinois, from March 29 to April 2, 2025.
-
3 weeks ago | 
psychiatrictimes.com | Leah Kuntz
Spinogenix today announced open enrollment for its phase 2 trial of SPG302 for the treatment of individuals with schizophrenia, following clearance of its Investigational New Drug (IND) application by the US Food and Drug Administration (FDA). The US-based trial evaluating the efficacy, safety, and tolerability of once-daily dosing of SPG302 expands on trials underway in Australia.
-
3 weeks ago | 
psychiatrictimes.com | Leah Kuntz
In case you missed any important updates, here is a recap of this week in Psychiatric Times, including clinical trial news on solriamfetol for attention-deficit/hyperactivity disorder (ADHD), exclusive content on the joint statement for psychiatric organizations defending the safety of psychotropic medications, and more information on acquired brain injury in honor of Brain Injury Awareness Month.
-
1 month ago | 
psychiatrictimes.com | Leah Kuntz
Axsome Therapeutics today announced that the FOCUS phase 3 trial of solriamfetol for the treatment of attention-deficit/hyperactivity disorder (ADHD) achieved its primary and key secondary endpoints, demonstrating statistically significant improvements in ADHD symptoms and disease severity compared with placebo.
-
1 month ago | 
psychiatrictimes.com | Leah Kuntz
Neurocrine Biosciences presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia (TD) among most patients treated with once-daily valbenazine (Ingrezza) capsules, at the 2025 Psychiatry Update Conference in Chicago.1 "These findings further establish Ingrezza as a highly effective long-term treatment option for individuals living with tardive dyskinesia, regardless of their underlying psychiatric condition, including schizophrenia,...
